Lv22
110 积分 2025-10-16 加入
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
19小时前
待确认
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
1个月前
已完结
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
1个月前
已完结
皖公网安备34019202002308
